LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM), a healthcare services management company that licenses the PROMETA® treatment protocols designed to treat alcohol, methamphetamine and cocaine dependence, announced today that the PROMETA protocols have been licensed for use initially at up to four locations of the largest outpatient substance dependence providers in Massachusetts, Preventive Medicine Associates (PMA). PMA operates 17 facilities in Massachusetts that all treat addictive disorders.
